Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders-Reference-Cited by-同舟云学术

Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders

Published:2015-11-23 Issue:23 Volume:58 Page:9154-9170
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Hobson Adrian D.¹,Harris Christopher M.¹,van der Kam Elizabeth L.²,Turner Sean C.²,Abibi Ayome¹,Aguirre Ana L.³,Bousquet Peter¹,Kebede Tegest¹,Konopacki Donald B.¹,Gintant Gary³,Kim Youngjae¹,Larson Kelly³,Maull John W.¹,Moore Nigel S.¹,Shi Dan¹,Shrestha Anurupa³,Tang Xiubo⁴,Zhang Peng⁴,Sarris Kathy K.³

Affiliation:

1. AbbVie Bioresearch Center, 381 Plantation Street, Worcester, Massachusetts 01605, United States

2. AbbVie Deutschland GmbH & Co KG, Knollstrasse 50, 67061 Ludwigshafen, Germany

3. AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States

4. Shanghai ChemPartner Co. Ltd., Building 10, 998 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai 201203, China

Funder

AbbVie

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5b00928

Reference33 articles.

1. Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier

2. Harris, C.; Hobson, A.; Wilson, N. S.Agonists and antagonists of the S1P5receptor, and methods of uses thereof. WO2010093704, 2010.

3. Van der Kam, E.; Turner, S.; van Bergeijk, J.; Mueller, R.; Mezler, M.; Bespalov, A.; Hobson, A.; Harris, C. M.; Rendenbach-Mueller, B.; Schoemaker, H.The use of selective sphingosine-1-phosphate receptor 5 agonists for the treatment of neurodegenerative disorders such as Alzheimer’s disease and lysosomal storage diseases such as Niemann Pick C disease.Alzheimer’s Association International Conference, AAIC,Copenhagen,July 12–17, 2014, abstract and presentation.

4. Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptors

5. Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Re-emergence of T lymphocyte-mediated synaptopathy in progressive multiple sclerosis;Frontiers in Immunology;2024-06-07

2. The Current Landscape in the Development of Small-molecule Modulators Targeting Sphingosine-1-phosphate Receptors to Treat Neurodegenerative Diseases;Current Topics in Medicinal Chemistry;2024-04-26

3. 1-Phosphate receptor agonists: A promising therapeutic avenue for ischemia-reperfusion injury management;International Immunopharmacology;2024-04

4. The medicinal chemistry evolution of antibody–drug conjugates;RSC Medicinal Chemistry;2024

5. Current advancements in therapy for Niemann-Pick disease: progress and pitfalls;Expert Opinion on Pharmacotherapy;2023-05-21